

PROGRAMME AND PRICES 2025

Prices are excluding VAT

ANNUAL SUBSCRIPTION		
The annual subscription fee is mandatory for each participant.		
DESCRIPTION	PRICE (EURO) #	PRODUCT CODE
Annual Subscription Fee: Result submission via ECAT website / survey report via website as pdf	158.00	101

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
MAIN PROGRAMME							
Thrombophilia - I: Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free)	4	2025-M1	2025-M2	2025-M3	2025-M4	430.00	402
Thrombophilia - II APC Resistance	4	2025-M1	2025-M2	2025-M3	2025-M4	175.00	417
Coagulation Factor - I Factor VIII (clot and chromogenic activity), IX (clot and chromogenic activity), XI:C and XII:C	4	2025-M1	2025-M2	2025-M3	2025-M4	220.00	406
Coagulation Factor - II Factor II:C, V:C, VII:C and X:C	4	2025-M1	2025-M2	2025-M3	2025-M4	220.00	407
Von Willebrand Factor parameters (antigen, ristocetin cofactor activity, activity, collagen binding, multimers, Factor VIII)	4	2025-M1	2025-M2	2025-M3	2025-M4	326.00	408
ADAMTS13 - I (activity and antigen)	4	2025-M1	2025-M2	2025-M3	2025-M4	230.00	409
ADAMTS13 - II (antibodies)	2		2025-M2		2025-M4	150.00	410
ADAMTS13 - III (functional inhibitor)	2		2025-M2		2025-M4	196.00	419
Factor XIII (activity and antigen)	4	2025-M1	2025-M2	2025-M3	2025-M4	162.00	411
Fibrinolysis - I Plasminogen, Antiplasmin	4	2025-M1	2025-M2	2025-M3	2025-M4	158.00	412
Fibrinolysis - II t-PA, PAI-1	4	2025-M1	2025-M2	2025-M3	2025-M4	158.00	413
LUPUS PROGRAMME							
Lupus Anticoagulant / Antiphospholipid Antibodies	4	2025-L1	2025-L2	2025-L3	2025-L4	210.00	404
D-DIMER PROGRAMME							
D-Dimer	4	2025-D1	2025-D2	2025-D3	2025-D4	160.00	405

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES								PRICE (EURO) #	PRODUCT CODE
SCREEN PROGRAMME											
Screen - I: APTT, PT/INR and Fibrinogen	8	2025-S1	2025-S2	2025-S3	2025-S4	2025-S5	2025-S6	2025-S7	2025-S8	276.00	501
Screen - II: Thrombin Time, Reptilase Time	8	2025-S1	2025-S2	2025-S3	2025-S4	2025-S5	2025-S6	2025-S7	2025-S8	276.00	502

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
APTT / PT MIXING TEST PROGRAMME							
APTT / PT Mixing Test	4	2025-Mix1	2025-Mix2	2025-Mix3	2025-Mix4	230.00	503

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
HAEMOPHILIA PROGRAMME							
Haemophilia Factor VIII (clot and chromogenic activity) Factor IX (clot and chromogenic activity)	4	2025-H1	2025-H2	2025-H3	2025-H4	278.00	418
Factor VIII inhibitor	2		2025-H2		2025-H4	218.00	202
Factor IX Inhibitor	2	2025-H1		2025-H3		218.00	201
Emicizumab	2		2025-H2		2025-H4	218.00	223
Kovaltry (Bayer)	2	2025-H1		2025-H3		215.00	228
Jivi (Bayer)	2	2025-H1		2025-H3		215.00	229
Esperoct (Novo Nordisk)	2		2025-H2		2025-H4	215.00	230
NovoEight (Novo Nordisk)	2		2025-H2		2025-H4	215.00	231
Refixia (Novo Nordisk)	2		2025-H2		2025-H4	215.00	232

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
FDP Programme							
Fibrin(ogen) Degradation Products	4	2025-F1	2025-F2	2025-F3	2025-F4	160.00	420

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
ANTICOAGULATION PROGRAMME							
Unfractionated Heparin Monitoring (anti-Xa)	4	2025-A1	2025-A2	2025-A3	2025-A4	142.00	414
Low-Molecular Weight Heparin Monitoring (anti-Xa)	4	2025-A1	2025-A2	2025-A3	2025-A4	142.00	415
Orgaran (anti-Xa)	2		2025-A2		2025-A4	72.00	205
Fondaparinux (anti-Xa)	2		2025-A2		2025-A4	72.00	206
Rivaroxaban (anti-Xa)	2		2025-A2		2025-A4	72.00	207
Apixaban (anti-Xa)	2		2025-A2		2025-A4	72.00	208
Edoxaban (anti-Xa)	2		2025-A2		2025-A4	72.00	221
Argatroban (anti-IIa/dTT)	2		2025-A2		2025-A4	72.00	209
Dabigatran (anti-IIa/dTT)	2		2025-A2		2025-A4	72.00	210

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
THROMBOELASTOGRAPHY PROGRAMME							
ROTEM delta <input type="checkbox"/> 1 instrument / 1 set of samples ROTEM <input type="checkbox"/> 2 instruments / 2 sets of samples ROTEM <input type="checkbox"/> 3 instruments / 3 sets of samples ROTEM	4	2025-T1	2025-T2	2025-T3	2025-T4	362.00 615.40 868.80	212 213 214
ROTEM sigma <input type="checkbox"/> 1 instrument / 1 set of samples ROTEM <input type="checkbox"/> 2 instruments / 2 sets of samples ROTEM <input type="checkbox"/> 3 instruments / 3 sets of samples ROTEM	4	2025-T1	2025-T2	2025-T3	2025-T4	362.00 615.40 868.80	215 216 217
TEG <input type="checkbox"/> 1 instrument / 1 set of samples TEG <input type="checkbox"/> 2 instruments / 2 sets of samples TEG <input type="checkbox"/> 3 instruments / 3 sets of samples TEG	4	2025-T1	2025-T2	2025-T3	2025-T4	362.00 615.40 868.80	218 219 220
CLOT-PRO <input type="checkbox"/> 1 instrument / 1 set of samples CLOT-PRO <input type="checkbox"/> 2 instruments / 2 sets of samples CLOT-PRO <input type="checkbox"/> 3 instruments / 3 sets of samples CLOT-PPRO	4	2025-T1	2025-T2	2025-T3	2025-T4	362.00 615.40 868.80	224 225 226
THROMBIN GENERATION PROGRAMME							
Thrombin Generation Test	2	2025-TG1		2025-TG3		164.00	203
PFA PROGRAMME							
PFA-100/200	2	2025-P1		2025-P3		516.00	222
LTA PROGRAMME							
Platelet Light Transmission Aggregometry	2		2025-LTA2		2025-LTA4	400.00	233

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
HIT PROGRAMME							
HIT - I (immunological testing)	2	2025-HIT1		2025-HIT3		246.00	204
HIT- II (functional testing)	2		2025-HIT2		2025-HIT4	295.00	234

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
ACT PROGRAMME							
Note: samples will be distributed separately from other surveys. For details see Survey Schedule 2025							
Activated Clotting Time	2		2025-ACT1		2025-ACT2	140.00	504

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
POCT INR QC PROGRAMME							
No annual subscription fee applicable if only participating in the POCT INR QC Programme.							
POCT INR QC Programme for CoaguChek INR Monitors (any type)	4	2025-Q1	2025-Q2	2025-Q3	2025-Q4	494.00	301
* Annual shipping costs for countries outside Europe: on request.							

DESCRIPTION	ORGANISED BY	NUMBER OF SURVEYS	SURVEY PERIOD(S)	PRICE (EURO) #	PRODUCT CODE
OTHER SURVEYS					
Post Analytical Platelet Function EQA (electronic surveys)	Nascola, USA	2	Spring, Autumn	262.00	701
Platelet Dense Granule exercise (electronic surveys)	Nascola, USA	2	Spring, Autumn	262.00	704
Whole Blood Impedance Platelet Aggregation (electronic surveys)	Nascola, USA	2	Spring, Autumn	230.00	707
Case study on bleeding disorders (will be distributed together with survey 2025-3)	ECAT	1	2025-3	120.00	703
Case study on anticoagulation bridging (will be distributed together with survey 2025-2)	ECAT	1	2025-2	120.00	706
Pre- and post-analytical electronic survey in haemostasis	ECAT	1	Autumn	85.00	705

HOMOCYSTEINE (In co-operation with the DEKS, Denmark)

DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES				PRICE (EURO) #	PRODUCT CODE
Homocysteine	4	2025-01	2025-02	2025-03	2025-04	195.00	1001

MOLECULAR BIOLOGY (In co-operation with the SPMD, Germany)

SURVEY	DESCRIPTION	NUMBER OF SURVEYS	SURVEY CODES		PRICE (EURO) #	PRODUCT CODE
MOLECULAR GENETICS MG1						
MG1 Set A	For details: see below	2	MG1 1/25	MG1 2/25	114.00	601
MG1 Set B	For details: see below	2	MG1 1/25	MG1 2/25	114.00	602
MG1 Set C	For details: see below	2	MG1 1/25	MG1 2/25	114.00	603
MG1 Set D	For details: see below	2	MG1 1/25	MG1 2/25	114.00	604
MG1 Set E	For details: see below	2	MG1 1/25	MG1 2/25	114.00	605
MG1 Set F	For details: see below	2	MG1 1/25	MG1 2/25	114.00	606
MOLECULAR GENETICS MG2						
MG2 Set A	For details: see below	2	MG2 1/25	MG2 2/25	114.00	801
MG2 Set B	For details: see below	2	MG2 1/25	MG2 2/25	114.00	802
MG2 Set C	For details: see below	2	MG2 1/25	MG2 2/25	114.00	803
MG2 Set D	For details: see below	2	MG2 1/25	MG2 2/25	114.00	804
MG2 Set E	For details: see below	2	MG2 1/25	MG2 2/25	114.00	805
MG2 Set F	For details: see below	2	MG2 1/25	MG2 2/25	114.00	806
DNA SEQUENCING SQ						
Sequencing and interpretation		2	SQ 1/25	SQ 2/25	266.00	901
DNA ISOLATION DI						
DNA Isolation and genotyping (For details: see below)		2	DI 1/25	DI 2/25	141.00	902
Extra costs for shipment of Molecular Biology surveys	Per registration for one or more of the Molecular Biology surveys an annual fee of € 68.50 will be charged.					

Details MG1

- Set A:**
- FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025)
 - FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963)
 - Methylenetetrahydrofolate reductase (MTHFR)
 - MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133)
 - MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131)
 - PAI-I 4G5G (SERPINE1, NM_000602.5:c.-820G[(4_5)], rs1799762)
- Set B:**
- FXIII V34L (F13A1, NM_000129.4:c.103G>T, rs5985)
 - GPIIIa (ITGB3, NM_000212.3:c.176T>C, rs5918)
 - beta-Fibrinogen g-455a (FGB, NM_005141.4:c.-463G>A, rs1800790)
 - Vitamin K epoxide reductase complex subunit 1 (VKORC1)
 - VKORC1 G-1639 (VKORC1, NM_024006.6:c.-1639G>A, rs9923231)
 - VKORC1 C1173T (VKORC1, NM_024006.6:c.174-136C>T, rs9934438)
 - FXII c46t (F12, NM_000505.4:c.-4T>C rs1801020)
 - FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595)
- Set C:**
- Alpha-1-Antitrypsin, (serpin family A member1)
 - AAT-PI*S (SERPINA1, NM_000295.5:c.863A>T, rs17580)
 - AAT-PI*Z (SERPINA1, NM_000295.5:c.1096G>A, rs28929474)
 - AAT - Genotyping
 - AAT- (Alpha-1-Antitrypsin-Genotyping)
 - Apolipoprotein E (APOE)
 - ApoE2 (APOE, NM_000041.4:c.526C>T, rs7412)
 - ApoE4 (APOE, NM_000041.4:c.388T>C, rs429358)
 - ApoE - Genotyping
 - ApoB100 (APOB, NM_000384.3:c.10580G>A, rs5742904)
 - ACE I/D (ACE, NM_000789.3:c.2306-117_2306-116insAF118569.1:g.14094_14382, rs1799752)
 - CETP B1/B2 (CETP, NM_000078.3:c.118+279G>A, rs708272)
- Set D:**
- Aldolase, fructose-bisphosphate B (ALDOB)
 - AldoB 149 (ALDOB, NM_000035.4:c.448G>C, rs1800546)
 - AldoB 174 (ALDOB, NM_000035.4:c.524C>A, rs76917243)
 - AldoB 334 (ALDOB, NM_000035.4:c.1005C>G, rs78340951)
 - Hereditary Hemochromatosis (HFE)
 - HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945)
 - HFE S65C (HFE, NM_000410.4:c.193A>T, rs1800730)
 - HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562)
 - LCT c-13910t (LCT, NM_005915.6:c.1917+326C>T, rs4988235)
 - Nucleotide binding oligomerization domain containing 2 (NOD2)
 - NOD R702W (NOD2, NM_001370466.1:c.2023C>T, rs2066844)
 - NOD G908R (NOD2, NM_001370466.1:c.2641G>C, rs2066845)
 - NOD L1007finsC (NOD2, NM_001370466.1:c.2938dup, rs2066847)
- Set E:**
- ATP7B-C3207A (ATP7B, NM_000053.4:c.3207C>A, rs76151636)
 - FSAP Marburg-I (HABP2, NM_004132.5:c.1601G>A, rs7080536)
 - ITGA2 GplIIa C807T (ITGA2, NM_002203.4:c.759C>T, rs1126643)
 - Col1A1 SP1 (Col1A1, NM_000088.4:c.104-441G>T, rs1800012)
 - Vitamin D receptor (VDR)
 - VDR BsmI (VDR, NM_000376.3:c.1024+283G>A, rs1544410)
 - VDR ApaI (VDR, NM_000376.3:c.1025-49G>T, rs7975232)
 - VDR TaqI (VDR, NM_000376.3:c.1056T>C, rs731236)
- Set F:**
- Faktor VII (R353Q) (F7, NM_019616.4:c.1172G>A, rs6046)
 - AT3 Cambridge Typ I/II (SERPINC1, NM_000488.4:c.1246G>C>T, rs121909548)
 - CYP3A5*3 (CYP3A5, NM_000777.5:c.219-237A>G, rs776746)

Details MG2

- Set A:** Thiopurine S-methyltransferase (TPMT)
- TPMT*2 (TPMT, NM_000367.5:c.238G>C, rs1800462)
 - TPMT*3B (TPMT, NM_000367.5:c.460G>A, rs1800460)
 - TPMT*3C (TPMT, NM_000367.5:c.719A>G, rs1142345)
 - TPMT - Genotyping
 - CYP2C8*3 (CYP2C8, NM_000770.3:c.1196A>G, rs10509681)
Cytochrom P450 2C9 (CYP2C9)
 - CYP2C9*2 (CYP2C9, NM_000771.4:c.430C>T, rs1799853)
 - CYP2C9*3 (CYP2C9, NM_000771.4:c.1075A>C, rs1057910)
 - CYP2C9 - Genotyping
 - UGT1A1*28 (UGT1A1, NM_000463.3:c.-41_-40dupTA, rs3064744)
Dihydropyrimidine dehydrogenase (DPYD)
 - DPYD*2A (DPYD, NM_000110.4:c.1905+1G>A, rs3918290)
 - DPYD*13 (DPYD, NM_000110.4:c.1679T>G, rs55886062)
 - DPYD p.D949V (DPYD, NM_000110.4:c.2846A>T, rs67376798)
 - DPYD c.1129-5923C>G (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182)
 - DPYD c.1236G>A (DPYD, NM_000110.4:c.1236G>A, rs56038477)
 - DPYD HapB3 (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182,
NM_000110.4:c.1236G>A, rs56038477)
 - DPD activity score acc. to CPIC
 - DPD activity score acc. to DGHO
 - BCHE A (D70G) (BCHE, NM_000055.4:c.293A>G, rs1799807)
 - BCHE K (A567T) (BCHE, NM_000055.4:c.1699G>A, rs1803274)
- Set B:** KRAS proto-oncogene, GTPase (KRAS)
- KRAS p.G12/p.G13 (KRAS, NP_004976.2:p.G12/G13)
 - KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530)
 - KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529)
 - KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535)
 - KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441)
 - KRAS p.G12 (KRAS, NP_004976.2:p.G12)
 - KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530)
 - KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529)
 - KRAS p.G13 (KRAS, NP_004976.2:p.G13)
 - KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535)
 - KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441)
 - KRAS p.Q61 (KRAS, NP_004976.2:p.Q61)
 - KRAS p.Q61 (KRAS, NM_004985.5:c.181C>G>A, rs121913238)
 - KRAS p.Q61 (KRAS, NM_004985.5:c.182A>T>G>C, rs121913240)
 - KRAS p.Q61 (KRAS, NM_004985.5:c.183A>T>C, rs17851045)
 - BRAF p.V600 (BRAF, NP_004324.2:p.V600E/K)
 - BRAF V600E (BRAF, NM_004333.6:c.1799T>A, rs113488022)
 - BRAF V600K (BRAF, NM_004333.6:c.1798_1799delinsAA, rs121913227)
 - c-KIT p.D816V (KIT, NM_000222.3:c.2447A>T, rs121913507)
 - NRAS (NRAS, NP_002515.1:p.Q61)
 - NRAS (NRAS, NM_002524.5:c.181C>T>G>A, rs121913254)
 - NRAS (NRAS, NM_002524.5:c.182A>T>G>C, rs11554290)
 - NRAS (NRAS, NM_002524.5:c.183A>T>C, rs121913255)
- Set C:**
- HLA-B*27:01 (HLA-B, NM_005514.8)
 - TNF alpha 238 (TNF, NM_000594.3:c.-418G>A, rs361525)
 - TNF alpha 308 (TNF, NM_000594.3:c.-488G>A, rs1800629)

- Set D:** Cytochrome P450 2D6 (CYP2D6)
- CYP2D6*2-296 (CYP2D6*2, NM_000106.6:c.886C>T, rs16947)
 - CYP2D6*2-486 (CYP2D6*2, NM_000106.6:c.1457G>C, rs1135840)
 - CYP2D6*3 (CYP2D6*3, NM_000106.6:c.775del, rs35742686)
 - CYP2D6*4 (CYP2D6*4, NM_000106.6:c.506-1G>A, rs3892097)
 - CYP2D6*6 (CYP2D6*6, NM_000106.6:c.454del, rs5030655)
 - CYP2D6*7 (CYP2D6*7, NM_000106.6:c.971A>C, rs5030867)
 - CYP2D6*8 (CYP2D6*8, NM_000106.6:c.505G>T, rs5030865)
 - CYP2D6*9 (CYP2D6*9, NM_000106.6:c.841_843del, rs5030656)
 - CYP2D6*10 (CYP2D6*10, NM_000106.6:c.100C>T, rs1065852)
 - CYP2D6*17 (CYP2D6*17, NM_000106.6:c.320C>T, rs28371706)
 - CYP2D6*35 (CYP2D6*35, NM_000106.6:c.31G>A, rs769258)
 - CYP2D6*41 (CYP2D6*41, NM_000106.6:c.985+39G>A, rs28371725)
 - CYP2D6*5 (CYP2D6, Deletion)
 - CYP2D6*xN (CYP2D6, Duplication/Amplification)
 - Cytochrome P450 2C19 (CYP2C19)
 - CYP2C19*2 (CYP2C19, NM_000769.4:c.681G>A, rs4244285)
 - CYP2C19*3 (CYP2C19, NM_000769.4:c.636G>A, rs4986893)
 - CYP2C19*17 (CYP2C19, NM_000769.4:c.-806C>T, rs12248560)
 - CYP2C19 - Genotyping
- Set E:**
- HLA-B*57:01 (HLA-B, NM_005514.8)
 - Cytochrome P450 2B6 (CYP2B6)
 - CYP2B6*4 (CYP2B6, NM_000767.5:c.785A>G, rs2279343)
 - CYP2B6*9 (CYP2B6, NM_000767.5:c.516G>T, rs3745274)
 - CYP2B6*6 (CYP2B6, NM_000767.5:c.785A>G, rs2279343 + NM_000767.5:c.516G>T, rs3745274)
 - ABCB1 c.3435T>C (ABCB1, NM_001348946.2:c.3435T>C, rs1045642)
 - CCR5-del32bp (CCR5, NM_001394783.1:c.554_585del, rs333)
- Set F:**
- IL28B (C/T Polymorphism) (IFNL4, NM_001276254.2:c.151-152G>A, rs12979860)
 - IL6 G(-174)C (IL6, NM_000600.4:c.-237C>G, rs1800795)
 - CYP3A4*22 (CYP3A4, NM_017460.6:c.522-191C>T, rs35599367)

Details DNA Isolation and genotyping

- FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025)
- FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595)
- FV-Cambridge (F5, NM_000130.5:c.1001G>C, rs118203906)
- FV-Hong-Kong (F5, NM_000130.5:c.1000A>G, rs118203905)
- FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963)
- Methylenetetrahydrofolate reductase (MTHFR)
- MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133)
- MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131)
- Hereditary Hemochromatosis (HFE)
- HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945)
- HFE S65C (HFE, NM_000410.4:c.193A>T, rs1800730)
- HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562)

DETAILED SAMPLE INFORMATION

Description	Survey Code	Number of different samples per survey	Number of vials per sample code	Component
Thrombophilia - I: Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free)	M	2	2	Plasma, lyophilised
Thrombophilia - II APC Resistance	M	2	1	Plasma, lyophilised
Coagulation Factor - I Factor VIII (clot and chromogenic activity), IX (clot and chromogenic activity), XI:C and XII:C	M	2	2	Plasma, lyophilised
Coagulation Factor - II Factor II:C, V:C, VII:C and X:C	M	2	2	Plasma, lyophilised
Von Willebrand Factor parameters (antigen, ristocetin cofactor activity, activity, collagen binding, multimers, Factor VIII)	M	2	2	Plasma, lyophilised
ADAMTS13 - I (activity and antigen)	M	2	1	Plasma, lyophilised
ADAMTS13 - II (antibodies)	M	2	1	Plasma, lyophilised
ADAMTS13 - III (functional inhibitor)	M	2	1	Plasma, lyophilised
Factor XIII (activity and antigen)	M	2	1	Plasma, lyophilised
Fibrinolysis - I Plasminogen, Antiplasmin	M	2	1	Plasma, lyophilised
Fibrinolysis - II t-PA, PAI-1	M	2	1	Plasma, lyophilised
Haemophilia Factor VIII / Factor IX (clot and chromogenic activity)	H	2	1	Plasma, lyophilised
Factor VIII inhibitor	H	2	1	Plasma, lyophilised
Factor IX Inhibitor	H	2	1	Plasma, lyophilised
Emicizumab	H	2	1	Plasma, lyophilised
Kovaltry	H	2	1	Plasma, lyophilised
Jivi	H	2	1	Plasma, lyophilised
Esperoct	H	2	1	Plasma, lyophilised
NovoEight	H	2	1	Plasma, lyophilised
Refixia	H	2	1	Plasma, lyophilised
Lupus Anticoagulant / Antiphospholipid Antibodies	L	1	2	Plasma, lyophilised
Unfractionated Heparin Monitoring (anti-Xa)	A	2	1	Plasma, lyophilised
Low-Molecular Weight Heparin Monitoring (anti-Xa)	A	2	1	Plasma, lyophilised
Orgaran (anti-Xa)	A	2	1	Plasma, lyophilised
Fondaparinux (anti-Xa)	A	2	1	Plasma, lyophilised
Rivaroxaban (anti-Xa)	A	2	1	Plasma, lyophilised
Apixaban (anti-Xa)	A	2	1	Plasma, lyophilised
Edoxaban (anti-Xa)	A	2	1	Plasma, lyophilised
Argatroban (anti-IIa/dTT)	A	2	1	Plasma, lyophilised
Dabigatran (anti-IIa/dTT)	A	2	1	Plasma, lyophilised
D-Dimer	D	2	1	Plasma, lyophilised
Screen - I APTT, PT/INR and Fibrinogen	S	2	1	Plasma, lyophilised
Screen - II Thrombin Time, Reptilase Time	S	2	1	Plasma, lyophilised
Thrombin Generation Test	TG	3	1	Plasma, lyophilised
PFA-100/200	P	2	2	tubes ± additives
ROTEM delta (samples per set)	T	2	1	Plasma, lyophilised
ROTEM sigma (samples per set)	T	2	1	Plasma, lyophilised
TEG (samples per set)	T	2	1	Plasma, lyophilised
CLOT-PRO (samples per set)	T	2	1	Plasma, lyophilised
HIT - I (immunological testing)	HIT	2	1	Plasma, lyophilised
HIT - II (functional testing)	HIT	2	1	Plasma, lyophilised
POCT INR QC Programme	Q	4	1	Plasma, lyophilised
APTT / PT Mixing Test Programme	MIX	2	1	Plasma, lyophilised

DETAILED SAMPLE INFORMATION

Description	Survey Code	Number of different samples per survey	Number of vials per sample code	Component
Activated Clotting Time	ACT	2	1	Artificial whole blood
FDP	F	2	1	Plasma, lyophilised
Platelet Light Transmission Aggregometry (LTA)	LTA	2	1	tubes ± additives
Homocysteine		2	1	Plasma, liquid
Post Analytical Platelet Function EQA (electronic survey)		-	-	-
Platelet Dense Granule exercise (electronic survey)		-	-	-
Whole Blood Impedance Platelet Aggregation (electronic survey)		-	-	-
Case study on bleeding disorders		1	1 or 2	Plasma, lyophilised
Case study on anticoagulation bridging		1	1	Plasma, lyophilised
Pre- and post-analytical electronic surveys in haemostasis		-	-	-
Molecular Genetics MG1		2	1	DNA preparation, lyophilised
Molecular Genetics MG2		2	1	DNA preparation, lyophilised
DNA Sequencing		5	1	DNA preparation, lyophilised
DNA Isolation		2	1	Full blood, K-EDTA

LIST OF PARAMETERS

Parameter	Module	Survey Code
Activated Clotting Time	Activated Clotting Time	ACT
ADAMTS-13 activity	ADAMTS13 - I	M
ADAMTS-13 antigen	ADAMTS13 - I	M
ADAMTS-13 antibodies	ADAMTS13 - II	M
ADAMTS-13 functional antibodies	ADAMTS13 - III	M
Anticardiolipin antibodies (IgG, IgM)	Lupus Anticoagulant / Antiphospholipid Antibodies	L
Antithrombin activity	Thrombophilia - I	M
Antithrombin antigen	Thrombophilia - I	M
APC Resistance	Thrombophilia - II	M
Apixaban (anti-Xa)	Apixaban	A
APTT (clotting time / ratio)	Screen – I	S
APTT Mixing Test	APTT / PT Mixing Test	Mix
Argatroban (anti-IIa / dTT)	Argatroban	A
CLOT-PRO	CLOT-PRO	T
Dabigatran (anti-IIa / dTT)	Dabigatran	A
D-Dimer	D-Dimer	D
Edoxaban (anti-Xa)	Edoxaban	A
Emicizumab	Emicizumab	H
Esperoct	Haemophilia	H
Factor II:C	Coagulation Factor - II	M
Factor V:C	Coagulation Factor - II	M
Factor VII:C	Coagulation Factor - II	M
Factor VIII (clot and chromogenic)	Coagulation Factor - I / Haemophilia	M / H
Factor VIII Inhibitor	Factor VIII Inhibitor	H
Factor IX (clot and chromogenic)	Coagulation Factor - I / Haemophilia	M / H
Factor IX Inhibitor	Factor IX Inhibitor	H
Factor X:C	Coagulation Factor - II	M
Factor XI:C	Coagulation Factor - I	M
Factor XII:C	Coagulation Factor - I	M
Factor XIII activity	Factor XIII	M
Factor XIII antigen	Factor XIII	M
Fibrinogen (Clauss)	Screen – I	S
Fibrinogen (Derived)	Screen – I	S
Fibrinogen Degradation Products	FDP	F
Fondaparinux (anti-Xa)	Fondaparinux	A
β2-Glycoprotein I antibodies (IgG, IgM)	Lupus Anticoagulant / Antiphospholipid Antibodies	L
HIT (immunological testing)	HIT - I	HIT
HIT (functional testing)	HIT - II	HIT
Homocysteine	Homocysteine	-
INR	Screen – I	S
INR POCT	POCT INR QC Programme	Q
Jivi	Haemophilia	H

LIST OF PARAMETERS

Parameter	Module	Survey Code
Kovaltry	Haemophilia	H
Low-Molecular Heparin (anti-Xa)	Low-Molecular Heparin Monitoring	A
Lupus Anticoagulant	Lupus Anticoagulant / Antiphospholipid Antibodies	L
NovoEight	Haemophilia	H
Orgaran (anti-Xa)	Orgaran	A
PAI-1 activity	Fibrinolysis - II	M
PAI-I antigen	Fibrinolysis - II	M
PFA-100/200	PFA-100/200	P
Platelet Light Transmission Aggregometry (LTA)	LTA	LTA
Plasminogen activity	Fibrinolysis - I	M
Plasmin Inhibitor (antiplasmin) activity	Fibrinolysis - I	M
Protein C activity (chromogenic / clotting)	Thrombophilia - I	M
Protein C antigen	Thrombophilia - I	M
Protein S activity	Thrombophilia - I	M
Protein S antigen (total and free)	Thrombophilia - I	M
PT (clotting time, percentage)	Screen - I	S
PT Mixing Test	APTT / PT Mixing Test	Mix
Refixia	Haemophilia	H
Reptilase Time (clotting time / ratio)	Screen - II	S
Rivaroxaban (anti-Xa)	Rivaroxaban	A
ROTEM delta	ROTEM delta	T
ROTEM sigma	ROTEM sigma	T
TEG	TEG	T
Thrombin Generation Test	Thrombin Generation Test	TG
Thrombin Time (clotting time / ratio)	Screen - II	S
t-PA antigen	Fibrinolysis - II	M
Unfractionated Heparin (anti-Xa)	Unfractionated Heparin Monitoring	A
Von Willebrand Factor antigen	Von Willebrand Factor Parameters	M
Von Willebrand Factor ristocetin cofactor activity	Von Willebrand Factor Parameters	M
Von Willebrand Factor activity	Von Willebrand Factor Parameters	M
Von Willebrand Factor collagen binding	Von Willebrand Factor Parameters	M
Von Willebrand Factor multimers	Von Willebrand Factor Parameters	M
Von Willebrand Factor / Factor VIII	Von Willebrand Factor Parameters	M